Results 51 to 60 of about 218,137 (295)

Staurosporine induces necroptotic cell death under caspase-compromised conditions in U937 cells [PDF]

, 2012
For a long time necrosis was thought to be an uncontrolled process but evidences recently have revealed that necrosis can also occur in a regulated manner.
Barna, Gabor, Bauer, Pal I., Dunai, Zsuzsanna A., Imre, Gergely, Korcsmaros, Tamas, Mihalik, Rudolf, Petak, Istvan   +6 more
core   +3 more sources

Role of Programmed Death‐Ligand 1 in Cancer

The FASEB Journal, 2019
Programmed death‐1 (PD‐1) is an immunoregulatory receptor on cytotoxic T cells that suppresses the immune system upon interaction with its two ligands, programmed death ligand‐1 (PD‐L1) and programmed death ligand‐2 (PD‐L2). Programmed death‐ligand 1 (PD‐L1), previously known as “CD279”, is made up of 268 amino acids with a crystal structure.
Tina Link, Megha Dilip, Olivia Caruso, Margaret Chang, Abhinav Kona, Jesse Liu, Ajay Nathan, Anita Singh, Shiloh Thomas‐Wilkinson   +8 more
openaire   +1 more source

Programmed death-ligand 1 regulates ameloblastoma growth and recurrence. [PDF]

Int J Oral Sci
Abstract Tumor cell-intrinsic programmed death-ligand 1 (PD-L1) signals mediate tumor initiation, progression and metastasis, but their effects in ameloblastoma (AM) have not been reported. In this comprehensive study, we observed marked upregulation of PD-L1 in AM tissues and revealed the robust correlation between elevated PD-L1 expression ...
Zhang L, Lin H, Liang J, Liu X, Zhang C, Man Q, Li R, Zhao Y, Liu B.   +8 more
europepmc   +4 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

The expression of programmed death 1 in tumor-infiltrating lymphocytes of hepatocellular carcinoma and its correlation with prognosis

Zhongguo aizheng zazhi, 2021
Background and purpose: Programmed death 1 (PD-1) plays an important role in the regulation of peripheral immune tolerance. The expression of PD-1 in tumor-infiltrating lymphocytes of hepatocellular carcinoma (HCC) and the relationship between PD-1 ...
肖　锋, 肖静文, 邵建国, 陈丽燕, 顾春燕   +4 more
doaj  

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. [PDF]

, 2016
Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck ...
Berger, Raanan, Burtness, Barbara, Cheng, Jonathan D, Chow, Laura QM, Chung, Hyun Cheol, Dolled-Filhart, Marisa, Eder, Joseph Paul, Geva, Ravit, Gupta, Shilpa, Haddad, Robert, Kang, Hyunseok, Keam, Bhumsuk, Lee, Se-Hoon, Lin, Chia-Chi, Mahipal, Amit, Mehra, Ranee, Meister, Amy, Muro, Kei, Pathiraja, Kumudu, Seiwert, Tanguy Y, Tahara, Makoto, Weiss, Jared   +21 more
core   +2 more sources

Linking neurogenesis, oligodendrogenesis, and myelination defects to neurodevelopmental disruption in primary mitochondrial disorders

FEBS Letters, EarlyView.
Mitochondrial remodeling shapes neural and glial lineage progression by matching metabolic supply with demand. Elevated OXPHOS supports differentiation and myelin formation, while myelin compaction lowers mitochondrial dependence, revealing mitochondria as key drivers of developmental energy adaptation.
Sahitya Ranjan Biswas, Porter L. Tomsick, Alicia M. Pickrell, Paul D. Morton   +3 more
wiley   +1 more source

Efficacy of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis

Tzu Chi Medical Journal, 2023
Objectives: This study aimed to investigate the efficacy and safety of programmed cell death-1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors in patients with advanced hepatocellular carcinoma (HCC).
Tzu-Rong Peng, Li-Jou Yang, Ta-Wei Wu
doaj   +1 more source

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. [PDF]

, 2018
Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by ...
Chamie, Karim, Crosetti, Anna M, Cummings, Amy L, Drakaki, Alexandra, Faiena, Izak, Pantuck, Allan J   +5 more
core   +1 more source

Human T cell glycosylation and implications on immune therapy for cancer [PDF]

, 2020
Glycosylation is an important post-translational modification, giving rise to a diverse and abundant repertoire of glycans on the cell surface, collectively known as the glycome.
Callewaert, Nico, De Bousser, Elien, Festjens, Nele, Meuris, Leander   +3 more
core   +1 more source